Can Cosentyx (secukinumab) cause Crohn’s disease?
Cosentyx (secukinumab) is an IL‑17A inhibitor used for conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. IL‑17–blocking drugs have been reported to trigger or worsen inflammatory bowel disease in some patients, and Crohn’s disease is among the conditions that have been described.
Because individual risk varies, the safest practical approach is to treat it as a possible risk and watch for symptoms consistent with Crohn’s (new or worsening diarrhea, abdominal pain, weight loss, blood or mucus in stool).
What do patients typically notice if IL‑17 blockers affect the gut?
People who develop Crohn’s-like symptoms on treatment often report:
- persistent diarrhea
- abdominal cramping or pain
- fatigue
- weight loss
- blood or mucus in stool
If those symptoms start after beginning Cosentyx or start worsening on therapy, clinicians usually reassess the cause (including ruling out infection) and may consider holding or stopping the drug if Crohn’s is suspected.
Is Crohn’s a known “class effect” for IL‑17 inhibitors?
Reports of new or worsened inflammatory bowel disease have been seen with IL‑17 pathway inhibitors. That means Crohn’s risk is not usually described as something unique to Cosentyx alone, but as a risk that can occur with IL‑17 blockade. The key clinical point is that any new gut symptoms while on Cosentyx should be evaluated promptly, especially if you have a history of Crohn’s disease or other inflammatory bowel disease.
Who should be especially cautious about starting or continuing Cosentyx?
Extra caution is typically warranted if you:
- already have Crohn’s disease or ulcerative colitis
- have a past history of inflammatory bowel disease
- develop new or worsening GI symptoms during treatment
Clinicians may weigh benefits versus risks and monitor symptoms closely.
What should you do if you develop Crohn’s symptoms on Cosentyx?
Contact your prescribing clinician soon if you develop symptoms like persistent diarrhea or abdominal pain. Do not self-adjust the dose without medical guidance. The prescriber may:
- evaluate for infection and other causes of diarrhea
- consider GI referral and diagnostic testing for Crohn’s
- consider changing therapy if Crohn’s is suspected
If you want, tell me what symptoms you’re having and how long you’ve been on Cosentyx, and whether you have any history of Crohn’s or ulcerative colitis, and I can help you understand what to discuss with your clinician.
Sources
DrugPatentWatch.com: https://www.drugpatentwatch.com/